Profiles

Justin Cousins

UTAS Home Mr Justin Cousins

Justin Cousins

Lecturer in Pharmacy Practice

Room 3010 , Pharmacy

+61 3 6226 1005 (phone)

+61 3 6226 2870 (fax)

Justin.Cousins@utas.edu.au

Justin is a lecturer in pharmacy practice. He has a background in a variety of pharmacy areas within Australia and abroad. His experience includes: community pharmacy, medication management, hospital pharmacy research and academia.

Biography

Justin commenced his career as a community pharmacist. In this role he worked in a variety of locations and settings within Tasmania, far north Queensland and Dublin, Ireland. After returning to Tasmania, Justin began providing medication reviews and commenced tutoring roles at the University of Tasmania. He is currently undertaking a PhD researching adverse drug reactions in older people while coordinating the year 4 pharmacy practice units. He continues to work as a pharmacist in consultant and advisory roles.

Career summary

Qualifications

  • BPharm (1st Class Hons), Prescribing of Psychotropic Medication for Residential Aged Care Facility residents with dementia – A General Practitioner Survey, University of Tasmania, Australia, 2015
  • Bachelor of Pharmacy, University of Tasmania, Australia, 1999

Memberships

Professional practice

  • Pharmaceutical Society of Australia
  • Australian Association of Consultant Pharmacists
  • Pharmaceutical Defence Limited – Local advisory committee member

Administrative expertise

Justin was a director of a consultant pharmacy business. In this business he had roles coordinating pharmacist services.

Teaching

Pharmacy Practice, Therapeutics in Practice, Pharmacotherapeutics

Teaching responsibility

Justin is the unit coordinator for CSA457 Pharmacy Skills in Practice 4a, and CSA430 Pharmacy Practice

View more on Mr Justin Cousins in WARP

Expertise

  • Adverse Drug Reactions
  • Medication management
  • Medication in older people
  • Residential aged care

Research Themes

Justin’s research aligns with the University’s research theme of Better Health through researching medication safety in older people. His PhD is investigating adverse drug reactions in older people following hospital discharge.

Current projects

Justin’s current research is focusing on adverse drug reactions in older people in both the aged care setting and after hospital discharge.

Fields of Research

  • Clinical pharmacy and pharmacy practice (321403)
  • Clinical pharmacology and therapeutics (321402)
  • Rheumatology and arthritis (320223)
  • Aged health care (420301)
  • Preventative health care (420605)

Research Objectives

  • Evaluation of health and support services (200299)
  • Clinical health (200199)
  • Health related to ageing (200502)
  • Evaluation of health outcomes (200202)
  • Health education and promotion (200203)
  • Allied health therapies (excl. mental health services) (200301)
  • Expanding knowledge in the health sciences (280112)

Publications

Total publications

9

Journal Article

(5 outputs)
YearCitationAltmetrics
2021Cousins J, Parameswaran Nair N, Curtain C, Bereznicki B, Wilson K, et al., 'Preventing adverse drug reactions after hospital discharge (PADR-AD): Protocol for a randomised-controlled trial in older people', Research in Social and Administrative Pharmacy ISSN 1934-8150 (2021) [Refereed Article]

DOI: 10.1016/j.sapharm.2021.09.007 [eCite] [Details]

Co-authors: Parameswaran Nair N; Curtain C; Bereznicki B; Wilson K; Bereznicki L

Tweet

2020Curtain CM, Chang JY, Cousins J, Parameswaran Nair N, Bereznicki B, et al., 'Medication regimen complexity index prediction of adverse drug reaction-related hospital admissions', The Annals of Pharmacotherapy, 54, (10) Article 996-1000. ISSN 1060-0280 (2020) [Refereed Article]

DOI: 10.1177/1060028020919188 [eCite] [Details]

Citations: Scopus - 2Web of Science - 2

Co-authors: Curtain CM; Parameswaran Nair N; Bereznicki B; Bereznicki L

Tweet

2020Lim R, Bereznicki LR, Corlis M, Kalisch Ellet LM, Kang AC, et al., 'Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial: study protocol for a randomised controlled trial in residential aged-care facilities assessing frailty as the primary outcome', BMJ open, 10, (4) Article e032851. ISSN 2044-6055 (2020) [Refereed Article]

DOI: 10.1136/bmjopen-2019-032851 [eCite] [Details]

Citations: Scopus - 1Web of Science - 1

Co-authors: Bereznicki LR; Williams M

Tweet

2017Cousins JM, Bereznicki LRE, Cooling NB, Peterson GM, 'Prescribing of psychotropic medication for nursing home residents with dementia: a general practitioner survey', Clinical Interventions in Aging, 12 pp. 1573-1578. ISSN 1178-1998 (2017) [Refereed Article]

DOI: 10.2147/CIA.S146613 [eCite] [Details]

Citations: Scopus - 11Web of Science - 10

Co-authors: Bereznicki LRE; Cooling NB; Peterson GM

Tweet

2016Curtain CM, Williams M, Cousins JM, Peterson GM, Winzenberg T, 'Vitamin D supplementation in Tasmanian nursing home residents', Drugs and Aging, 33, (10) pp. 747-754. ISSN 1170-229X (2016) [Refereed Article]

DOI: 10.1007/s40266-016-0398-6 [eCite] [Details]

Citations: Scopus - 5Web of Science - 4

Co-authors: Curtain CM; Williams M; Peterson GM; Winzenberg T

Tweet

Conference Publication

(4 outputs)
YearCitationAltmetrics
2018Thompson A, Cousins J, Curtain C, Williams M, 'Magnesium deficiency with proton pump inhibitors: is it more common than we thought?', NPS MedicineWise Conference, National Medicine Symposium (NMS), 30 May - 1 June 2018, Canberra, Australia (2018) [Conference Extract]

[eCite] [Details]

Co-authors: Thompson A; Curtain C; Williams M

2017Toh L, Thompson AJ, Shah A, Cousins JM, Jackson S, et al., ''Good prescribing is a bit like good driving; everybody thinks they're a good driver.' An exploratory study on the barriers and facilitators to using quality prescribing indicators (QPIs) in general practice', APSA-ASCEPT Joint Meeting, 5 - 8 December 2017, Brisbane, Australia (2017) [Conference Extract]

[eCite] [Details]

Co-authors: Toh L; Thompson AJ; Jackson S; Cooling NB; Peterson GM

2016Thompson AJ, Cousins JM, Hoyle D, Wimmer BC, 'Polypharmacy, hyperpolypharmacy and age - the implications for medication management services', National Medicines Symposium, 19-20 May, 2016, Canberra, Australia (2016) [Conference Extract]

[eCite] [Details]

Co-authors: Thompson AJ; Hoyle D; Wimmer BC

2015Williams Mackenzie, Cousins JM, Curtain CM, Peterson GM, Winzenberg TM, 'Preliminary results of Vitamin D supplementation in residents of aged care facilities', APSA ASCEPT Conference, 29 November - 2 December, 2015, Hobart, Tasmania (2015) [Conference Extract]

[eCite] [Details]

Co-authors: Williams Mackenzie; Curtain CM; Peterson GM; Winzenberg TM

Grants & Funding

Funding Summary

Number of grants

2

Total funding

$3,121,927

Projects

Preventing Adverse Drug Reactions in the Elderly (2019 - 2022)$274,000
Description
Based on our prospective adverse drug reaction (ADR) registry:115% of medical admissions to Tasmanian public hospitals in elderly patients were ADR-related,89% were preventable,17% patients had a repeat ADR within 12 months, andOne third of patients with repeat ADRs experienced the same ADR caused by the same medications.From this clinical registry, we developed and validated an ADR risk prediction score (PADR-EC).2We hypothesise that ADR risk stratification during hospitalisation and communication of this risk, together with recommendations that target the specific risk factors identified, to GPs at discharge will reduce the risk of ADR-related hospitalisation.Design: A randomised controlled trial (RCT) at the Royal Hobart Hospital, the major public hospital in Tasmania.Population: Over 12-months, 1000 patients ≥65 years with unplanned admissions to medical wards will be recruited and randomly allocated to intervention or control groups.Intervention: A researcher will perform an ADR risk assessment using the PADR-EC Score,2 which is the sum of points assigned to 5 independent predictors of ADR-related hospitalisation. Based on the PADR-EC Score and the specific risk factors identified, recommendations to reduce the risk of ADRs will be determined.Recommendations will relate to:post-discharge medication management services, monitoring of specific parameters/medications, and de-prescribing strategies.The PADR-EC Score and recommendations will be communicated to the patient and clinical team during hospitalisation, and the patients GP, alongside the usual information, in the electronic discharge summary. Control: Usual hospital care, with GPs receiving the standard discharge summary.Follow up: All participants will be followed by the research team for 12-months to identify ADRs (including their management and outcome) and health services received.Outcomes: ADR-related hospitalisation (primary); ADRs requiring hospital treatment, change in therapy or specific treatment (secondary). The study will be powered to detect a 5% difference in the primary outcome
Funding
HCF Health and Medical Research Foundation ($274,000)
Scheme
Grant-Health Services Research Program (HCF)
Administered By
University of Tasmania
Research Team
Bereznicki LRE; Curtain CM; Bereznicki BJ; Cousins JM; Connolly M; Adamczewski B; McKenzie D; Simpson T; Barratt A; Webber E; Parameswaran Nair N
Period
2019 - 2022
ReMInDAR Trial Reducing Medicine Induced Deterioration and Adverse Reactions Trial (2018 - 2020)$2,847,927
Description
This randomised controlled trial will assess a pharmacist led intervention to reduce medicine induced deterioration and adverse reactions. Medicine induced deterioration encompasses the spectrum of side effects that are frequently not recognised as medication related but are misattributed as geriatric syndromes, frailty or changes due to aging. The aim of the service is to enable early identification of signs and symptoms of medicine- induced deterioration so that worsening frailty and subsequent adverse events, such as injurious falls, fractures and delirium are prevented. In implementing the service, the pharmacist will use a suite of validated tools to assist in the detection of signs and symptoms of medicine-induced deterioration. The validated tools will encompass assessments to monitor changes in cognition, change in 24-hour movement behavior, including sleep, as well as grip strength. In addition, pharmacists will assess the potential for adverse medicine events via review of the resident care assessment record and through patient or carer reported changes in health since the medicine regimen was changed. The pharmacist service will be compared with usual care. The trial, involving 500 patients will take place in aged-care facilities in South Australia and Tasmania. Evaluation will encompass health program, clinical and economic evaluation. The expected clinical outcome is a reduction in medication-induced deterioration, as measured by change in frailty score. Adverse events will be measured as a secondary outcome. The cost- effectiveness evaluation will assess cost per adverse event avoided.
Funding
Department of Health (Cth) ($2,847,927)
Scheme
Pharmacy Trial Program (Tranche 2)
Administered By
University of Tasmania
Research Team
Bereznicki LRE; Roughead L; Pratt Nicole; Parfitt G; Cousins JM; Williams Mackenzie
Period
2018 - 2020